May 5, 2020 / 5:05 AM / a month ago

BRIEF-Sanofi and Regeneron post more positive results for Libtayo® (cemiplimab) product

May 5 (Reuters) - Sanofi SA:

* REG-LIBTAYO® (CEMIPLIMAB) SHOWS CLINICALLY MEANINGFUL AND DURABLE RESPONSES IN SECOND-LINE ADVANCED BASAL CELL CARCINOMA

* OBJECTIVE RESPONSES SEEN IN 29% OF PATIENTS WITH LOCALLY ADVANCED BASAL CELL CARCINOMA (BCC)

* SANOFI AND REGENERON PLAN REGULATORY SUBMISSIONS ON THIS PRODUCT IN 2020

* IN A PRELIMINARY ANALYSIS, OBJECTIVE RESPONSES SEEN IN 21% OF PATIENTS WITH METASTATIC BCC

* APPROXIMATELY 85% OF PATIENTS WHO RESPONDED TO LIBTAYO MAINTAINED THEIR RESPONSE FOR AT LEAST ONE YEAR Further company coverage: (Reporting by Sudip Kar-Gupta)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below